Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS systems. It also offers Senza HFX iQ platform that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, the company provides HFX AdaptivAI, a pain management platform that powers the HFX iQ SCS system, as well as surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is based in Redwood City, California.
Market Headwinds | Nevro faces declining sales and market share in the spinal cord stimulation sector, with challenges expected to persist through 2025 |
Strategic Pivot | Explore Nevro's product launches and acquisitions, including HFX AdaptivAI and Vyrsa SI joint therapy, aimed at diversifying revenue streams |
Financial Outlook | Analysts project 2025 sales of $425 million, with price targets ranging from $4 to $7, reflecting cautious sentiment amid market uncertainties |
Value Proposition | Delve into Nevro's strategic review process and strong cash position, which could unlock shareholder value despite current market challenges |
Metrics to compare | NVRO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVROPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.9x | −6.3x | −0.5x | |
PEG Ratio | 0.10 | 0.01 | 0.00 | |
Price/Book | 0.9x | 3.9x | 2.6x | |
Price / LTM Sales | 0.5x | 2.8x | 3.0x | |
Upside (Analyst Target) | 1.2% | 54.0% | 54.1% | |
Fair Value Upside | Unlock | −3.4% | 9.4% | Unlock |